TEDA Biomedical: April 2026 Monthly Return Shows Stable 2.13 Billion Share Base and Public-Float Compliance

Bulletin Express

May 04

Tianjin TEDA Biomedical Engineering Company Limited reported no changes in either authorised or issued share capital for the month ended 30 April 2026.

• Authorised share capital remained at 2.13 billion shares, split between 1.44 billion H Shares and 0.70 billion Domestic Shares, each with a par value of RMB 0.10. Total authorised capital therefore stayed at RMB 213.39 million.

• Issued share capital was unchanged at 2.13 billion shares, comprising 1.44 billion H Shares and 0.70 billion Domestic Shares. No treasury shares were held.

• The company confirmed that its H Share public float continued to meet the minimum 25% threshold required under Hong Kong listing rules.

• There were no share options, warrants, convertible securities, share repurchases or other equity movements during the reporting period.

The filing, submitted on 4 May 2026, underscores TEDA Biomedical’s unchanged capital structure and ongoing compliance with Hong Kong Exchange requirements.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1136337885"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1136337885\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1136337885?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-04 10:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1136337885","market":"hk","top_or_hot":-1,"title":"TEDA Biomedical: April 2026 Monthly Return Shows Stable 2.13 Billion Share Base and Public-Float Compliance","media":"Bulletin Express","content":"<p>Tianjin TEDA Biomedical Engineering Company Limited reported no changes in either authorised or issued share capital for the month ended 30 April 2026.</p>\n<p>• Authorised share capital remained at 2.13 billion shares, split between 1.44 billion H Shares and 0.70 billion Domestic Shares, each with a par value of RMB 0.10. Total authorised capital therefore stayed at RMB 213.39 million.</p>\n<p>• Issued share capital was unchanged at 2.13 billion shares, comprising 1.44 billion H Shares and 0.70 billion Domestic Shares. No treasury shares were held.</p>\n<p>• The company confirmed that its H Share public float continued to meet the minimum 25% threshold required under Hong Kong listing rules.</p>\n<p>• There were no share options, warrants, convertible securities, share repurchases or other equity movements during the reporting period.</p>\n<p>The filing, submitted on 4 May 2026, underscores TEDA Biomedical’s unchanged capital structure and ongoing compliance with Hong Kong Exchange requirements.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>TEDA Biomedical: April 2026 Monthly Return Shows Stable 2.13 Billion Share Base and Public-Float Compliance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTEDA Biomedical: April 2026 Monthly Return Shows Stable 2.13 Billion Share Base and Public-Float Compliance\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-05-04 10:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Tianjin TEDA Biomedical Engineering Company Limited reported no changes in either authorised or issued share capital for the month ended 30 April 2026.</p>\n<p>• Authorised share capital remained at 2.13 billion shares, split between 1.44 billion H Shares and 0.70 billion Domestic Shares, each with a par value of RMB 0.10. Total authorised capital therefore stayed at RMB 213.39 million.</p>\n<p>• Issued share capital was unchanged at 2.13 billion shares, comprising 1.44 billion H Shares and 0.70 billion Domestic Shares. No treasury shares were held.</p>\n<p>• The company confirmed that its H Share public float continued to meet the minimum 25% threshold required under Hong Kong listing rules.</p>\n<p>• There were no share options, warrants, convertible securities, share repurchases or other equity movements during the reporting period.</p>\n<p>The filing, submitted on 4 May 2026, underscores TEDA Biomedical’s unchanged capital structure and ongoing compliance with Hong Kong Exchange requirements.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"08189","symbol_name":"泰达生物","start_time":0,"source_url":"","article_id":"1136337885","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1136337885","pubTimestamp":1777860149,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Tianjin TEDA Biomedical Engineering Company Limited reported no changes in either authorised or issued share capital for the month ended 30 April 2026. • Authorised share capital remained at 2.13...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"08189":"泰达生物"},"translate_title":"泰达生物医疗：2026年4月月报表显示稳定21.3亿股基础和公众持股合规","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"08189":1},"content_text":"Tianjin TEDA Biomedical Engineering Company Limited reported no changes in either authorised or issued share capital for the month ended 30 April 2026.\n• Authorised share capital remained at 2.13 billion shares, split between 1.44 billion H Shares and 0.70 billion Domestic Shares, each with a par value of RMB 0.10. Total authorised capital therefore stayed at RMB 213.39 million.\n• Issued share capital was unchanged at 2.13 billion shares, comprising 1.44 billion H Shares and 0.70 billion Domestic Shares. No treasury shares were held.\n• The company confirmed that its H Share public float continued to meet the minimum 25% threshold required under Hong Kong listing rules.\n• There were no share options, warrants, convertible securities, share repurchases or other equity movements during the reporting period.\nThe filing, submitted on 4 May 2026, underscores TEDA Biomedical’s unchanged capital structure and ongoing compliance with Hong Kong Exchange requirements.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}